Monte Rosa Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating Activities | ||||||
| Net Income | $-38.6M | $-72.7M | $-135.4M | $-108.5M | $-74.0M | $-35.9M |
| Depreciation & Amortization | — | — | — | — | — | — |
| Depreciation | $8.4M | $8.1M | $6.2M | $3.7M | $2.1M | $537.0K |
| Amortization | $2.5M | $2.1M | $2.1M | $2.5M | — | — |
| Stock-Based Compensation | $18.9M | $18.1M | $16.7M | $11.7M | $5.2M | $354.0K |
| Net Cash from Operating Activities | $-22.8M | $42.0M | $-43.8M | $-92.5M | $-59.4M | $-23.1M |
| Investing Activities | ||||||
| Capital Expenditures | $4.7M | $4.0M | $19.0M | $12.9M | $9.7M | $3.4M |
| Business Acquisitions | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-101.8M | $-44.5M | $88.8M | $-219.2M | $-9.7M | $-3.4M |
| Financing Activities | ||||||
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | — |
| Stock Repurchases | — | — | — | — | — | — |
| Net Cash from Financing Activities | $30.4M | $98.9M | $27.5M | $20.5M | $377.6M | $60.1M |
| Net Change in Cash | $-94.3M | $96.4M | $72.5M | $-291.2M | $308.5M | $33.6M |
| Free Cash Flow | $-27.5M | $38.0M | $-62.8M | $-105.4M | $-69.1M | $-26.4M |